INPULSIS
2014
Nintedanib in Idiopathic Pulmonary Fibrosis
In 1,066 patients with idiopathic pulmonary fibrosis, nintedanib 150 mg twice daily slowed annual FVC decline compared with placebo.
Result
Primary endpoint: Annual rate of FVC decline
-115 vs -240 mL (INPULSIS-1) and -114 vs -207 mL (INPULSIS-2); both p<0.001. Diarrhoea >60%.
- Subtopic
- Antifibrotic: IPF
- Design
- Two replicate 52-week RCTs
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- ATS/ERS 2015 IPF
- Source
- Richeldi L, et al. N Engl J Med. 2014;370(22):2071-2082.doi 10.1056/NEJMoa1402584
Discussion & critique
Anchored FDA approval of nintedanib for IPF.